Richard T Wang1, Stanley F Nelson. 1. aDepartment of Human Genetics, David Geffen School of Medicine bCenter for Duchenne Muscular Dystrophy cDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Abstract
PURPOSE OF REVIEW: This review aims to describe the benefits and limitations of using the Duchenne Connect patient registry to provide information particularly in regard to active treatment choices in Duchenne muscular dystrophy and their impact on disease progression. RECENT FINDINGS: Clinical trials and natural history studies are difficult for rare diseases like Duchenne muscular dystrophy. Using an online patient self-report survey model, Duchenne Connect provides relevant data that are difficult to gather in other ways. Validation of the overall dataset is supported by comparable mutational spectrum relative to other cohorts and demonstrated beneficial effect of corticosteroid use in prolonging ambulation. These types of analyses are provocative and allow multivariate analyses across the breadth of patient and physician medication and supplement practices. Because the data are self-reported and online, the barrier to participation is low and great potential exists for novel directions of further research in a highly participatory forum. SUMMARY: Patient registries for Duchenne and Becker muscular dystrophy (DBMD) are powerful tools for monitoring patient outcomes, comparing treatment options, and relating information between patients, researchers, and clinicians. Duchenne Connect is an online patient self-report registry for individuals with DBMD that facilitates aggregation of treatment modalities, outcomes, and genotype data and has played a vital role in furthering DBMD research, particularly in the USA, in a highly participatory and low-cost manner.
PURPOSE OF REVIEW: This review aims to describe the benefits and limitations of using the Duchenne Connect patient registry to provide information particularly in regard to active treatment choices in Duchenne muscular dystrophy and their impact on disease progression. RECENT FINDINGS: Clinical trials and natural history studies are difficult for rare diseases like Duchenne muscular dystrophy. Using an online patient self-report survey model, Duchenne Connect provides relevant data that are difficult to gather in other ways. Validation of the overall dataset is supported by comparable mutational spectrum relative to other cohorts and demonstrated beneficial effect of corticosteroid use in prolonging ambulation. These types of analyses are provocative and allow multivariate analyses across the breadth of patient and physician medication and supplement practices. Because the data are self-reported and online, the barrier to participation is low and great potential exists for novel directions of further research in a highly participatory forum. SUMMARY:Patient registries for Duchenne and Becker muscular dystrophy (DBMD) are powerful tools for monitoring patient outcomes, comparing treatment options, and relating information between patients, researchers, and clinicians. Duchenne Connect is an online patient self-report registry for individuals with DBMD that facilitates aggregation of treatment modalities, outcomes, and genotype data and has played a vital role in furthering DBMD research, particularly in the USA, in a highly participatory and low-cost manner.
Authors: Annemieke Aartsma-Rus; Judith C T Van Deutekom; Ivo F Fokkema; Gert-Jan B Van Ommen; Johan T Den Dunnen Journal: Muscle Nerve Date: 2006-08 Impact factor: 3.217
Authors: R T Moxley; S Ashwal; S Pandya; A Connolly; J Florence; K Mathews; L Baumbach; C McDonald; M Sussman; C Wade Journal: Neurology Date: 2005-01-11 Impact factor: 9.910
Authors: Catherine L Bladen; David Salgado; Soledad Monges; Maria E Foncuberta; Kyriaki Kekou; Konstantina Kosma; Hugh Dawkins; Leanne Lamont; Anna J Roy; Teodora Chamova; Velina Guergueltcheva; Sophelia Chan; Lawrence Korngut; Craig Campbell; Yi Dai; Jen Wang; Nina Barišić; Petr Brabec; Jaana Lahdetie; Maggie C Walter; Olivia Schreiber-Katz; Veronika Karcagi; Marta Garami; Venkatarman Viswanathan; Farhad Bayat; Filippo Buccella; En Kimura; Zaïda Koeks; Janneke C van den Bergen; Miriam Rodrigues; Richard Roxburgh; Anna Lusakowska; Anna Kostera-Pruszczyk; Janusz Zimowski; Rosário Santos; Elena Neagu; Svetlana Artemieva; Vedrana Milic Rasic; Dina Vojinovic; Manuel Posada; Clemens Bloetzer; Pierre-Yves Jeannet; Franziska Joncourt; Jordi Díaz-Manera; Eduard Gallardo; A Ayşe Karaduman; Haluk Topaloğlu; Rasha El Sherif; Angela Stringer; Andriy V Shatillo; Ann S Martin; Holly L Peay; Matthew I Bellgard; Jan Kirschner; Kevin M Flanigan; Volker Straub; Kate Bushby; Jan Verschuuren; Annemieke Aartsma-Rus; Christophe Béroud; Hanns Lochmüller Journal: Hum Mutat Date: 2015-03-17 Impact factor: 4.878
Authors: Richard T Wang; Cheri A Silverstein Fadlon; J Wes Ulm; Ivana Jankovic; Ascia Eskin; Ake Lu; Vanessa Rangel Miller; Rita M Cantor; Ning Li; Robert Elashoff; Anne S Martin; Holly L Peay; Nancy Halnon; Stanley F Nelson Journal: PLoS Curr Date: 2014-10-17
Authors: M D Bonifati; G Ruzza; P Bonometto; A Berardinelli; K Gorni; S Orcesi; G Lanzi; C Angelini Journal: Muscle Nerve Date: 2000-09 Impact factor: 3.217
Authors: Anna C Need; Vandana Shashi; Yuki Hitomi; Kelly Schoch; Kevin V Shianna; Marie T McDonald; Miriam H Meisler; David B Goldstein Journal: J Med Genet Date: 2012-05-11 Impact factor: 6.318
Authors: Miriam J Rodrigues; Gina L O'Grady; Graeme Hammond-Tooke; Alexa Kidd; Donald O Love; Ronelle K Baker; Richard H Roxburgh Journal: J Neuromuscul Dis Date: 2017
Authors: Mousumi Bose; David D Cuthbertson; Marsha A Fraser; Jean-Baptiste Roullet; K Michael Gibson; Dana R Schules; Kelly M Gawron; Melissa B Gamble; Kathryn M Sacra; Melisa J Lopez; William B Rizzo Journal: Mol Genet Metab Rep Date: 2020-12-10